The evolution of antiepileptic drug development and regulation

Epileptic Disorders

Volumn 12, Issue 1, 2010, Pages 3-15

  Arzimanoglou, Alexis ^a   Ben Menachem, Elinor ^b   Cramer, Joyce ^c   Glauser, Tracy ^d   Seeruthun, Rav ^e   Harrison, Miranda ^e  

^a INSERM   (France)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e EISAI CO LTD   (Japan)

Author keywords

Antiepileptic drugs; Clinical trials; Drug development; Patient reported outcome; QOL; Regulation

Indexed keywords

ANTICONVULSIVE AGENT; BRIVARACETAM; CARBAMAZEPINE; CARISBAMATE; ETIRACETAM; GANAXOLONE; PERAMPANEL; PHENOBARBITAL; PHENYTOIN; POTASSIUM BROMIDE; PRIMIDONE; RETIGABINE; THALIDOMIDE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ADD ON THERAPY; APLASTIC ANEMIA; BIRTH DEFECT; BLOOD TOXICITY; CLINICAL OBSERVATION; COARSE FACE; DISEASE MODEL; DRUG APPROVAL; DRUG CARCINOGENICITY; DRUG CONTROL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EPILEPSY; FOCAL EPILEPSY; FUNCTIONAL STATUS; GINGIVA HYPERPLASIA; HIRSUTISM; HUMAN; HYPONATREMIA; INFANTILE SPASM; IRRITABILITY; LIVER DYSFUNCTION; LIVER FAILURE; MENTAL INSTABILITY; NEEDS ASSESSMENT; NONHUMAN; PATIENT CARE; PERIPHERAL NEUROPATHY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REGISTER; REVIEW; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; STEVENS JOHNSON SYNDROME; STUDY DESIGN; TERATOGENICITY; THROMBOCYTOPENIA; TONIC CLONIC SEIZURE; TREATMENT OUTCOME; TRIGEMINUS NEURALGIA; VISUAL FIELD DEFECT; CLINICAL TRIAL; DRUG DEVELOPMENT; EVIDENCE BASED MEDICINE;

ANTICONVULSANTS; CLINICAL TRIALS AS TOPIC; DRUG AND NARCOTIC CONTROL; DRUG DISCOVERY; EPILEPSY; EVIDENCE-BASED MEDICINE; HUMANS; QUALITY OF LIFE;

EID: 77952294521     PISSN: 12949361     EISSN: 19506945     Source Type: Journal    
DOI: 10.1684/epd.2010.0303     Document Type: Review

References (90)

1. Annas GJ, Elias S. Thalidomide and the Titanic: reconstructing the technology tragedies of the twentieth century. Am J Public Health 1999; 89: 98-101. (Pubitemid 29281980)
2. Azarbayjani F, Danielsson BR. Phenytoin-induced cleft palate: evidence for embryonic cardiac bradyarrhythmia due to inhibition of delayed rectifier K+ channels resulting in hypoxiareoxygenation damage. Teratology 2001; 63: 152-60. (Pubitemid 32247063)
3. Beghi E, Annegers JF, Collaborative Group for the Pregnancy Registries in Epilepsy. Pregnancy registries in epilepsy. Epilepsia 2001; 42: 1422-5. (Pubitemid 33140618)
4. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 2000; 41: 1276-83.
5. Blom S. Trigeminal neuralgia: its treatment with a new anticonvulsant drug (G-32883). Lancet 1962; 1: 839-40.
6. Bonduelle M, Bouygues P, Sallou CI, Chemaly R. Expérimentation clinique de l'antiipileptique G 32 883 (Tegretol): résultats portant sur 100 cas observés en trois ans. Rev Neurol (Paris) 1964; 110: 209-15.
7. Boon P, Chauvel P, Pohlmann-Eden B, Otoul C, Wroe S. Doseresponse effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy. Epilepsy Res 2002; 48: 77-89.
8. Brodie MJ, Duncan R, Vespignani H, Solyom A, Bitenskyy V, Lucas C. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005; 46: 31-41. (Pubitemid 40179930)
9. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ, Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007; 68: 402-8.
10. Caldwell PH, Murphy SB, Butow PN, Craig JC. Clinical trials in children. Lancet 2004; 364: 803-11. (Pubitemid 39165102)
11. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000; 55: 236-42. (Pubitemid 30604624)
12. Chiron C, Dulac O, Pons G. Antiepileptic drug development in children: considerations for a revisited strategy. Drugs 2008; 68: 17-25.
13. Cramer JA, Smith DB, Mattson RH, Delgado Escueta AV, Collins JF. A method of quantification for the evaluation of antiepileptic drug therapy. Neurology 1983; 33 (3 Suppl. 1): 26-37. (Pubitemid 13147839)
14. Devereaux PJ, Yusuf S. The evolution of the randomized controlled trial and its role in evidence-based decision making. J Intern Med 2003; 254: 105-13. (Pubitemid 36900433)
15. Devi K, George S, Criton S, Suja V, Sridevi PK. Carbamazepine - the commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: a study of 7 years. Indian J Dermatol Venereol Leprol 2005; 71: 325-8. (Pubitemid 41376754)
16. Doll R, Hill AB. The mortality of doctors in relation to their smoking habits; a preliminary report. Br Med J 1954; 1: 1451-5.
17. Dong X, Leppik IE, White J, Rarick J. Hyponatremia from oxcarbazepine and carbamazepine. Neurology 2005; 65: 1976-8. (Pubitemid 43970125)
18. Duncan S. Teratogenesis of sodium valproate. Curr Opin Neurol 2007; 20: 175-80. (Pubitemid 46411503)
19. Dupont S, Striano S, Trinka E, et al. Flexible dosing of adjunctive zonisamide in the treatment of adult partial-onset seizures: a non-comparative, open-label study (ZEUS). Acta Neurol Scand, 2009 [Epub ahead of print].
20. Durelli L, Massazza U, Cavallo R. Carbamazepine toxicity and poisoning. Incidence, clinical features and management. Med Toxicol Adverse Drug Exp 1989; 4: 95-107.
21. Faught E, Ayala R, Montouris GG, Leppik IE, Zonisamide 922 Trial Group. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001; 57: 1774-9.
22. Felbamate (Felbatol®) Prescribing Information. Updated 06/2008. Available at: http://www.felbatol.com/pi.pdf (Accessed 3 February 2010).
23. Fertig EJ, Mattson RH. Carbamazepine. In: Engel J, Pedley TA, eds. Epilepsy: A Comprehensive Textbook, Vol.2. Philadelphia: Lippincott Williams & Wilkins, 2007: 1543-56.
24. French J, Smith M, Faught E, Brown L. Practice advisory: The use of felbamate in the treatment of patients with intractable epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 1999; 52: 1540-5. (Pubitemid 29220625)
25. French JA, Kanner AM, Bautista J, et al., Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1252-60.
26. Friedlander WJ. The rise and fall of bromide therapy in epilepsy. Arch Neurol 2000; 57: 1782-5.
27. Garofalo E. Obtaining pediatric indications for new anti-epileptic drugs: how and when. Epilepsy Res 2006; 68: 38-42. (Pubitemid 43052777)
28. Genton P, Gelisse P, Thomas P, Dravet C. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology 2000; 55: 1106-9.
29. Gilliam FG, Fessler AJ, Baker G, Vahle V, Carter J, Attarian H. Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology 2004; 62: 23-7. (Pubitemid 38082864)
30. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47: 1094-120. (Pubitemid 44086745)
31. Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008; 70: 1950-8.
32. GlaxoSmithKline and Valeant Pharmaceuticals International. Retigabine Regulatory Update. Press release, issued 02 November 2009. Available at: http://www.gsk.com/media/pressreleases/2009/2009-pressrelease-10122.htm (Accessed 10 February 2010).
33. Gowers WR. Epilepsy and other chronic convulsive diseases: their causes, symptoms, & treatment. London: Churchill, 1881.
34. Graham D. Neuropathology of vigabatrin. Br J Clin Pharmacol 1989; 27 (Suppl. 1): 43S-45S.
35. Hashizume Y, Hanada T, Ogasawara A, Ueno M, Nishizawa Y. Pharmacological profile of E2007: broad-spectrum anticonvulsant activity in rodent models of epilepsy. Poster presented at Neuroscience 2007, San Diego, CA, USA, 3-7 November, 2007.
36. th Annual Meeting of the American Academy of Neurology, Chicago, IL, USA, 12-19 April, 2008.
37. Hauptmann A. Luminal bei Epilepsie. Münch Med Wochenschr 1912; 59: 1907-9.
38. Heller AJ, Chesterman P, Elwes RD, et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiatry 1995; 58: 44-50.
39. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295-300.
40. Horn CS, Ater SB, Hurst DL. Carbamazepine-exacerbated epilepsy in children and adolescents. Pediatr Neurol 1986; 2: 340-5. (Pubitemid 17029893)
41. Johnson JP. Acquired craniofacial features associated with chronic phenytoin therapy. Clin Pediatr (Phila) 1984; 23: 671-4. (Pubitemid 15179778)
42. Kanner AM. Depression in epilepsy: a complex relation with unexpected consequences. Curr Opin Neurol 2008; 21: 190-4. (Pubitemid 351644162)
43. Krall RL, Penry JK, Kupferberg HJ, Swinyard EA. Antiepileptic drug development: I. History and a program for progress. Epilepsia 1978; 19: 393-408.
44. Krauss G, Biton V, Klapper J, et al. Determination of tolerability, safety, and efficacy of perampanel, a selective AMPA receptor antagonist, as adjunctive therapy in subjects with refractory partial epilepsy. Epilepsia 2009; 50 (Suppl. 10): 103. Abstract p476.
45. Krishnamurthy KB. Pregnancy and epilepsy: update on pregnancy registries. Curr Treat Options Neurol 2008; 10: 246-52.
46. Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001; 42: 1255-60. (Pubitemid 33070664)
47. Labar DR. Antiepileptic drug use during the first 12 months of vagus nerve stimulation therapy: a registry study. Neurology 2002; 59 (6 Suppl. 4): S38-43.
48. Lawden MC, Eke T, Degg C, Harding GF, Wild JM. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 1999; 67: 716-22.
49. Laxer KD. Guidelines for treating epilepsy in the age of felbamate, vigabatrin, lamotrigine, and gabapentin. West J Med 1994; 161: 309-14.
50. Lenz W. Klinische Missbildüngen nach Medikament: einnahme Während der Gravidität? Dtsch Med Wochenschr 1961; 86: 2555-65.
51. Liu Y, Yohrling GJ, Wang Y, et al. Carisbamate, a novel neuromodulator, inhibits voltage-gated sodium channels and action potential firing of rat hippocampal neurons. Epilepsy Res 2009; 83: 66-72.
52. Loiseau PJ. Clinical experience with new antiepileptic drugs: antiepileptic drugs in Europe. Epilepsia 1999; 40 (Suppl. 6): S3-8.
53. Lorge M. Klinische Erfahrungen mit einem neuen Antiepilepticum, Tegretol (G 32 883) mit besonderer Wirkung auf die epileptische Wesenveränderung. Schweiz Med Wochenschr 1963; 93: 1042-7.
54. Loring DW, Marino S, Meador KJ. Neuropsychological and behavioral effects of antiepilepsy drugs. Neuropsychol Rev 2007; 17: 413-25. (Pubitemid 350231552)
55. Matagne A, Margineanu DG, Kenda B, Michel P, Klitgaard H. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol 2008; 154: 1662-71.
56. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985; 313: 145-51. (Pubitemid 15047456)
57. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992; 327: 765-71.
58. McBride WG. Thalidomide and congenital abnormalities. Lancet 1961; 2: 1358-63.
59. Merritt H, Putnam TJ. Sodium diphenyl hydantoinate in the treatment of convulsive disorders. J Am Med Soc 1938; 111: 1068-73.
60. Monaghan EP, Navalta LA, Shum L, Ashbrook DW, Lee DA. Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity. Epilepsia 1997; 38: 1026-31. (Pubitemid 27382941)
61. Monaghan EP, McAuley JW, Data JL. Ganaxolone: a novel positive allosteric modulator of the GABA(A) receptor complex for the treatment of epilepsy. Expert Opin Invest Drugs 1999; 8: 1663-71. (Pubitemid 29460530)
62. Morrell MJ, Leppik I, French J, Ferrendelli J, Han J, Magnus L. The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res 2003; 54: 153-61. (Pubitemid 36776733)
63. National for Health and Clinical Excellence (NICE). The diagnosis and management of the epilepsies in adults and children in primary and secondary care. NICE Clinical Guideline 20 (CG20), October 2004. Available at : http://www.nice.org.uk/nicemedia/pdf/CG020fullguideline.pdf (Accessed 3 February 2010).
64. Nohria V, Giller E. Ganaxolone. Neurotherapeutics 2007; 4: 102-5.
65. Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008; 111: 3968-77.
66. Pearce JM. Bromide, the first effective antiepileptic agent. J Neurol Neurosurg Psychiatry 2002; 72: 412. (Pubitemid 34185223)
67. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002; 16: 695-714. (Pubitemid 35176854)
68. Prince HK, Conn PJ, Blackstone CD, Huganir RL, Levey AI. Down-regulation of AMPA receptor subunit GluR2 in amygdaloid kindling. J Neurochem 1995; 64: 462-5.
69. Rheims S, Cucherat M, Arzimanoglou A, Ryvlin P. Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med 2008; 5: e166.
70. Richens A. Clinical pharmacokinetics of phenytoin. Clin Pharmacokinet 1979; 4: 153-69.
71. Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 2006; 69: 273-94. (Pubitemid 44209049)
72. Rundfeldt C, Netzer R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits. Neurosci Lett 2000; 282: 73-6. (Pubitemid 30129172)
73. rd TR, Shellenberger MK. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia 2004; 45: 610-7.
74. Scheinfeld N. Impact of phenytoin therapy on the skin and skin disease. Expert Opin Drug Saf 2004; 3: 655-65. (Pubitemid 39530217)
75. Schindler W, Häfliger F. Über Derivate des Iminodibenzyls. Helv Chim Acta 1954; 37: 472-83.
76. Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993; 15: 67-73. (Pubitemid 23152402)
77. Seeruthun R, Yeates A, Ashworth S. A European registry of antiepileptic drug use in patients with Lennox-Gastaut syndrome. Epilepsia 2009; 50 (Suppl. 10): 35. Abstract p140.
78. Shah RR, Griffin JP. Regulation of human medicinal products in the European Union. In: Griffin JP, O'Grady J, eds. The Textbook of Pharmaceutical Medicine. Massachusetts: Blackwell, 2006: 489-534.
79. Shorvon SD, Löwenthal A, Janz D, Bielen E, Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 2000; 41: 1179-86.
80. Shorvon SD. Drug treatment of epilepsy in the century of the ILAE: the first 50 years, 1909-1958. Epilepsia 2009a; 50 (Suppl. 3): 69-92.
81. Shorvon SD. Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959-2009. Epilepsia 2009b; 50 (Suppl. 3): 93-130.
82. Singh G, Driever PH, Sander JW. Cancer risk in people with epilepsy: the role of antiepileptic drugs. Brain 2005; 128: 7-17. (Pubitemid 40073649)
83. Streptomycin in Tuberculosis Trials Committee. Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948; 2: 769-82.
84. Sztajnkrycer MD. Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol 2002; 40: 789-801. (Pubitemid 35423414)
85. Tohen M, Castillo J, Cole JO, Miller MG, de los Heros R, Farrer RJ. Thrombocytopenia associated with carbamazepine: a case series. J Clin Psychiatry 1991; 52: 496-8.
86. Vajda FJ, Hitchcock A, Graham J, O'Brien T, Lander C, Eadie M. The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Aust N Z J Obstet Gynaecol 2007; 47: 468-74. (Pubitemid 350075922)
87. Wheless JW, Clarke DF, Arzimanoglou A, Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord 2007; 9: 353-412. (Pubitemid 351147653)
88. Wild JM, Ahn HS, Baulac M, et al. Vigabatrin and epilepsy: lessons learned. Epilepsia 2007; 48: 1318-27. (Pubitemid 47063093)
89. Williams SWD. On the Efficacy of the bromide of potassium in epilepsy and certain psychical affections. Br J Psychiatry 1866; 11: 598-602.
90. Wirrell EC. Valproic acid-associated weight gain in older children and teens with epilepsy. Pediatr Neurol 2003; 28: 126-9. (Pubitemid 36434158)